Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a randomized double-blind placebo-controlled cannabinoid add-on study in adults with drug-resistant epilepsy
MOH_2019-12-19_008566Phase 2Not yet recruiting
- Sponsor
- BOL Pharma
- Start
- Nov 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cannabidiol, cannabidivarin and dronabinol in epilepsy (4 arms), sponsored by BOL Pharma. Planned start Nov 2019; status: not yet recruiting.
02
Drugs
cannabidiolcannabidivarindronabinol
03
Conditions
epilepsy
Beyond the preview
Go deeper on MOH_2019-12-19_008566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-12-19_008566.